NCT00072618View on ClinicalTrials.gov

Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

October 31, 2001

Study Completion Date

August 31, 2003

Conditions
NSCLC
Interventions
DRUG

Exisulind

Trial Locations (2)

60637

University of Chicago Medical Center, Chicago

80045

University of Colorado Health Sciences Center, Aurora

Sponsors

Collaborators (1)

OSI Pharmaceuticals
All Listed Sponsors
collaborator

OSI Pharmaceuticals

INDUSTRY

lead

Astellas Pharma Inc

INDUSTRY